SCYNEXIS, Inc. to Present at 35th Canaccord Genuity Annual Growth Conference
RESEARCH TRIANGLE PARK, N.C., Aug. 10, 2015 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that Marco Taglietti, M.D., SCYNEXIS' Chief Executive Officer, will present at the 35th Canaccord Genuity Annual Growth Conference at the InterContinental Boston Hotel in Boston on Wednesday, August 12, 2015, at 2:25 p.m. ET.
A live webcast will be available on the investors section of the Company's website: www.scynexis.com. A replay of the presentation will be available approximately two hours after the event and will be available for two weeks following the presentation.
About SCYNEXIS, Inc.
SCYNEXIS is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. We are developing our lead product candidate, SCY-078, a novel antifungal in Phase 2, as an oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. For more information, visit www.scynexis.com.
CONTACT: Media Relations
Heather Savelle
MacDougall Biomedical Communications
Tel: 781-235-3060
hsavelle@macbiocom.com
Investor Relations
Jillian Connell
The Trout Group LLC
Tel: 646.378.2956
jconnell@troutgroup.com
Released August 10, 2015